Tim Heffernan
@timheff5
ID:799841793185611776
19-11-2016 05:08:38
165 Tweets
354 Followers
334 Following
Another KRAS inhibitor enters the clinic. This is Boehringer Ingelheim orally bioavailable multiKRASi BI-3706674 currently undergoing dose escalation in WT KRAS amplified upper GI cancers.
clinicaltrials.gov/study/NCT06056…
Cc: David S. Hong MD Dr. Shubham Pant Tim Heffernan Norbert Kraut Daniel Gerlach
Team MD Anderson Cancer Center has landed at Kiawah for the Break Through Cancer summit. Ready for three days of #RadicalCollaboration !
#BTCsummit2023
Dr. Ron DePinho Giulio Draetta Tim Heffernan Clayton Boldt, Ph.D. Karen Lu Linghua Wang, MD, PhD Kate McAndrews Caroline Chung, MD Jesse Boehm Kari McHugh
We empower patients with #rarecancers to donate their tissue to research happening at leading institutions + labs through our platform Pattern.org.
Some of our partners are MD Anderson Cancer Center, Koch Institute at MIT & Dana-Farber, Broad Institute, Brigham and Women's Hospital, Aflac Cancer and Blood Disorders Center
Huge congratulations this morning to Raghu & especially two Kalluri Lab MVPs - Kate McAndrews Krishnan - for their double header this morning on KRAS inhibition in #PancreaticCancer !
The 1st in Developmental Cell and the 2nd in Cancer Cell 🧵 below:
Want to accelerate your research with industry collaboration?
Learn how from our Jean Gilbert, Dr. Tim Heffernan and Dr. Timothy Yap on June 4 from 9 – 9:30 a.m. in booth 14030 at #ASCO23 . Jean Gilbert @TimHeff5 ASCO #EndCancer [2/8]
In an interview w/ Endpoints News, our CEO Mike Nally & Tim Heffernan provide their perspectives on Generate’s newest collaboration with MD Anderson Cancer Center. Together, we are bringing #GenerativeAI into the field of oncology. Read the full article by Ryan Cross the Science Boss:
“The ability to build an expansive catalog of disease models opens new avenues to advance impactful medicines,” says our Dr. Timothy Heffernan of a collaboration with Xilis. Learn about it here: fal.cn/3w9Ut Tim Heffernan Scott Kopetz Katy Rezvani, M.D., Ph.D #EndCancer
Stellar team work between different groups at MD Anderson Cancer Center and the Break Through Cancer killing ras group there Tim Heffernan Anirban Maitra Kalluri Lab #endcancer
MD Anderson is collaborating with Xilis to support preclinical research to accelerate the development of novel cancer therapies. Learn about it here: fal.cn/3vT62 Tim Heffernan Scott Kopetz Katy Rezvani, M.D., Ph.D #Research #EndCancer
Thinking about my buddy Ken Scott. It’s been 5 years since we said goodbye to the original honey badger. His legacy lives on as we innovate new approaches to #endcancer . Cheers my friend!
“Our research raises the possibility that the AR and testosterone may be at play and offers a new target to improve response to treatment in both sexes,” says our Dr. Jennifer Wargo: fal.cn/3ptCA Jennifer Wargo MD @TimHeff5 #EndCancer
Stephanie T. Schmidt, PhD, on NSCLC: The Immunomodulatory Impact of Neoadjuvant Chemotherapy and Immune-Based Treatments ascopost.com/videos/sitc-20… #immunotherapy #LCSM #oncology #cancer #SITC21 MD Anderson Cancer Center
Inspiring panel discussion on “translating breakthroughs into clinical impact” as part of the MD Anderson Cancer Center Leading Edge of Cancer research symposium. Thanks to Cigall Kadoch Ross Levine Katy Rezvani, M.D., Ph.D Kevan Shokat for a fascinating discussion. #endcancer Cassian Yee Giannicola Genovese MD, PhD